EP4051222A1 - Composition containing prebiotic bacteria and licochalcone a - Google Patents
Composition containing prebiotic bacteria and licochalcone aInfo
- Publication number
- EP4051222A1 EP4051222A1 EP20800591.8A EP20800591A EP4051222A1 EP 4051222 A1 EP4051222 A1 EP 4051222A1 EP 20800591 A EP20800591 A EP 20800591A EP 4051222 A1 EP4051222 A1 EP 4051222A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cosmetic
- composition according
- skin
- dermatological
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 241000894006 Bacteria Species 0.000 title claims abstract description 24
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 title claims abstract description 22
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 title claims abstract description 22
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 title claims abstract description 22
- 235000013406 prebiotics Nutrition 0.000 title 1
- 239000002537 cosmetic Substances 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 239000006041 probiotic Substances 0.000 claims description 19
- 230000000529 probiotic effect Effects 0.000 claims description 19
- 235000018291 probiotics Nutrition 0.000 claims description 19
- 241000186427 Cutibacterium acnes Species 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 9
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 8
- 241000192087 Staphylococcus hominis Species 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 230000008092 positive effect Effects 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012459 cleaning agent Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 241000928573 Cutibacterium Species 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000036559 skin health Effects 0.000 abstract description 8
- 241000186660 Lactobacillus Species 0.000 description 18
- 229940039696 lactobacillus Drugs 0.000 description 18
- 230000001012 protector Effects 0.000 description 17
- 244000005714 skin microbiome Species 0.000 description 10
- 244000005700 microbiome Species 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 241000929684 Lactobacillus oryzae Species 0.000 description 3
- 241001647418 Lactobacillus paralimentarius Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001647783 Lactobacillus amylolyticus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186723 Lactobacillus bifermentans Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186842 Lactobacillus coryniformis Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000861211 Lactobacillus crustorum Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001647786 Lactobacillus delbrueckii subsp. delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000500356 Lactobacillus dextrinicus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241000186851 Lactobacillus mali Species 0.000 description 1
- 241000216456 Lactobacillus panis Species 0.000 description 1
- 241001643453 Lactobacillus parabuchneri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 108010042648 lactocin Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010067215 mersacidin Proteins 0.000 description 1
- JSWKNDSDVHJUKY-CYGWNLPQSA-N mersacidin Chemical compound C([C@@H](C(=O)N[C@@H]1[C@H](C)SC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H]1[C@H](C)SC[C@H]2C(=O)N[C@H](C(N/C=C/S[C@@H](C)C(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)[C@H](C)CC)NC(=O)[C@H]1[C@@H](SC[C@H](N)C(=O)N1)C)C1=CC=CC=C1 JSWKNDSDVHJUKY-CYGWNLPQSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Definitions
- composition with probiotic bacteria and licochalcone A Composition with probiotic bacteria and licochalcone A.
- the present invention relates to a cosmetic or dermatological composition which comprises at least one probiotic bacterial strain which has a positive effect on skin health when it settles on the skin, and licochalcone A.
- the invention also relates to a method for the cosmetic or dermatological treatment of the skin, in which the composition of the present invention is applied to the skin.
- the invention also relates to a method for producing the cosmetic or dermatological composition of the present invention.
- US 2018/0104283 A1 describes a method in which bacterial strains naturally occurring on the skin are supplied to the skin in order to displace potentially pathogenic microorganisms.
- WO 2016/172196 A1 describes a method for treating acne in a patient, in which live C. acnes strains are settled on the patient's skin.
- it has repeatedly proven difficult to establish a sufficient amount of the metabolically active bacterial strains on the skin Since the skin is densely populated by bacteria, bacteria that are applied to the skin must first establish themselves in the microbiome, which is difficult due to the limited nutrients and the complex interactions within the various bacteria in the microbiome.
- compositions and methods with which probiotic bacterial strains which have a positive effect on skin health can be settled in sufficient quantities on the skin and integrated into the microbiome.
- a cosmetic composition which comprises or consists of at least the following components: a) at least one probiotically active bacterial strain which has a positive effect on the health of the skin when it settles on the skin; b) Licochalcone A or a derivative thereof.
- the composition according to the invention comprises, as a first component, at least one probiotic bacterial strain which, when it settles on the skin, has a positive effect on skin health.
- probiotically effective means that the bacterial strain in question, when administered to humans in sufficient quantities, conveys health-promoting effects.
- the term is used in connection with those bacterial strains that settle on the skin after administration, ie multiply through cell division, and have a positive effect on skin health through their presence in the skin flora.
- bacteria of the genus Staphylococcus and Cutibacterium are particularly suitable as probiotically effective bacterial strains. These genera are those that are regularly represented in normal human skin flora.
- the at least one probiotically effective bacterial strain belongs to a species which is selected from the group consisting of Staphylococcus epidermidis, Staphylococcus hominis and Cutibacterium acnes.
- Staphylococcus epidermidis and Staphylococcus hominis are coagulase-negative, facultatively pathogenic, gram-positive bacteria that inhabit human skin and mucous membranes.
- the at least one S. epidermidis strain and / or the at least one S. hominis strain is not an antimicrobial strain.
- S. epidermidis strains and S. hominis strains are known which have developed resistance to conventional antibiotics such as penicillin and therefore cannot be treated with appropriate preparations. It has been described in the literature that S. epidermidis strains and S. hominis strains are actively involved in the control of the growth of pathogenic agents such as S. aureus strains in the natural skin flora. For this reason, too, the establishment of non-pathogenic S. epidermidis strains leads to an improvement in skin health.
- the species C. acnes refers to gram-positive, anaerobic, rod-shaped bacteria, which until 2016 were taxonomically grouped as Propionibacterium acnes.
- the species includes pathogenic and non-pathogenic representatives. According to current knowledge, pathogenic representatives of this species, C. acnes, contribute significantly to the development of acne in humans, while non-pathogenic strains are important for maintaining a stable microbiome composition.
- the species can be divided into three phylogenetically different types, which are referred to here as types I, II and III.
- Type I bacteria are further subdivided into subtypes IA, IB and IC.
- Subtype 1A is further divided into subgroups 1A1 and 1A2.
- Many non-pathogenic strains of C. acnes belong to (a) type I, subtype IA, subgroup IA2, (b) type I, subtype IB, or (c) type II.
- the composition according to the invention comprises at least one strain of the species C. acnes, this strain preferably belonging to (a) type I, subtype IA, subgroup IA2, (b) type I, subtype IB, or (c) type II heard.
- the composition comprises one or more C. acnes strains of type I, subtype IA, subgroup IA2.
- it comprises the composition of one or more C. acnes strains of type I, subtype IB.
- the composition comprises one or more C. acnes strains of type II.
- the composition according to the invention comprises in each case at least one strain of type I, subtype IA, subgroup IA2, at least one strain of type I, subtype IB, and at least one strain of type II. It is particularly preferred that the composition according to the invention comprises several strains of type I, subtype IA, subgroup IA2, in combination with several strains of type I, subtype IB, as well as several strains of type II.
- composition of the present invention comprises a total amount of probiotic bacteria in the range of 10 4 -10 11 CFU / ml, and more preferably in the range of 10 7 -10 1 ° CFU / ml.
- the composition according to the invention comprises the flavonoid licochalcone A or a derivative thereof as a second component.
- Licochalcone A has the following structure:
- Licochalcone A is a chemical compound that can be extracted from the root of Chinese liquorice (Glycyrrhiza inflata). It has anti-inflammatory, antibacterial, anti-parasitic and anti-cancer effects and is regularly used in cosmetic compositions to prevent skin irritation such as redness. It has been shown that licochalcone A improves the establishment of probiotic strains, such as strains of S. epidermidis, S. hominis or C. acnes, in the skin microbiome.
- Licochalcone A is preferably used in an amount of from 0.0001 to 10% by weight, particularly preferably from 0.001 to 7.5% by weight and particularly preferably from 0.01 to 5% by weight or from 0.1 to 0.5% by weight based on the total weight of the composition. It is therefore advantageous to use licochalcone A or a derivative thereof in an amount of at least 0.0001% by weight, at least 0.001% by weight, at least 0.01% by weight, at least 0.1% by weight, at least 1.0% by weight, at least 2.0% by weight, at least 3.0% by weight, at least 4.0% by weight, or at least 5.0% by weight, based on the total weight the composition to use.
- the composition of the present invention contains, in addition to the at least one probiotic bacterial strain and licochalcone A or a derivative thereof, also at least one protector strain of the genus Lactobacillus, which promotes the settlement of the probiotic bacterial strain.
- Bacteria of the genus Lactobacillus are gram-positive, microaerophilic or anaerobic bacteria that are taxonomically assigned to the Lactobacillaceae family. These are gram-positive, usually rod-shaped bacteria that ferment sugar and carbohydrates into lactic acids. Bacteria of the genus Lactobacillus are particularly well known from the food industry, where they are often used as starter cultures in the manufacture of dairy products. The genus includes various species that can be used without restriction within the scope of the present invention.
- Suitable species which can serve as protector strains in the compositions of the present invention include Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus delbrueckii subsp.
- lactis Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus amylovorus, Lactobacillus aviaries, Lactobacillus bifermentans, Lactobacillus brevis, Lacto bacillus casei, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus dextrinicus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus hilgardii , Lactobacillus iners, Lactobacillus jensenii, Lactobacillus mali, Lactobacillus oryzae, Lactobacillus panis, Lactobacillus para- buchneri, Lactobacillus paracasei, Lactobacillus paralimentarius, Lactobacillus paralimentarius, Lactobac
- the composition of the present invention comprises two or more protector strains, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 Lactobacillus strains.
- it is the at least one protector strain which is added to the composition according to the invention to a strain of the species Lactobacillus plantarum or Lactobacillus rhamnosus.
- the composition according to the invention comprises at least one strain of the species Lactobacillus plantarum and one strain of the species Lactobacillus rhamnosus.
- the composition according to the invention comprises several strains of the species Lactobacillus plantarum and several strains of the species Lactobacillus rhamnosus.
- the at least one protector strain which is an optional component of the composition of the present invention can produce an antibiotic substance.
- the antibiotic substance can be a bacteriocin that is produced by the Lacto bacillus and secreted into the surrounding medium.
- the protector strain preferably produces a bacteriocin which is selected from the group consisting of nisin, mersacidin, lactocin, acidocin B, and entereocin P.
- the protector strain contained in the composition according to the invention produces 2 or more of the named bacteriocins .
- the optional protector strain or strains are selected in terms of type and amount such that the at least one probiotically effective bacterial strain settles which is at least 2 times higher than the corresponding settlement of the Bacterial strain in the absence of the protector strain. It is even more preferable that the colonization of the at least one probiotic strain of bacteria should be at least 5 times, at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 75 times. times, at least 100 times, at least 500 times or at least 1000 times higher than the corresponding settlement of the bacterial strain in the absence of the protector strain.
- the effect of the protector strains can be measured in simple assays in which the composition of the present invention, which comprises at least one probiotic strain of bacteria, at least one Lactobacillus strain, and licochalcone A or a derivative thereof, is compared with a negative control.
- the composition of the present invention comprises a total amount of bacteria of the genus Lactobacillus in the range of 10 4 -10 9 CFU / ml, and more preferably in the range of 10 6 -10 8 CFU / ml.
- the protector trunks Compared to the probiotic strains can be contained in the composition in much smaller amounts. Since the protector strains only have to provide the probiotic strains with a growth advantage in the early phase of colonization of the skin, their permanent settlement is not necessary. Accordingly, the protector strains can be applied to the skin in significantly lower inoculation densities.
- the at least one protector strain in the skin flora of the subject to whom the composition is administered. This means that the at least one protector strain does not reproduce or only insufficiently reproduces on the skin of the subject. It is preferred that after 24 hours, preferably after 48 hours and more preferably after 72 hours, the at least one protector strain can no longer be detected on the skin of the subject, or only in a small amount.
- the composition according to the invention preferably also comprises at least one cosmetic auxiliary.
- This cosmetic auxiliary can be substances that are regularly used as auxiliary in cosmetic or dermatological products. These substances include antioxidants, solubilizers, vitamins, dyes, carriers, fillers, emulsifiers, humectants and the like.
- the cosmetic auxiliary is glycerol, panthenol, ubiquinone Q10 or hyaluronic acid.
- composition according to the invention is formulated for use on the skin, it will have a pH value which is in the neutral to slightly acidic range. Thus it is preferred that the composition have a pH of 4-8, and preferably 5-7.
- composition according to the invention is preferably an emulsion.
- This can be in the form of an oil-in-water emulsion or a water-in-oil emulsion.
- the water content in the composition is less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, and particularly preferably less than 0.5% (weight / Weight).
- the composition according to the invention is an anhydrous composition.
- composition according to the invention is preferably in the form of a gel, a cream, an ointment or a lotion.
- composition according to the invention preferably does not comprise any silicone oil, mineral oil or polyethylene glycol.
- Cosmetic and dermatological compositions usually contain one or more preservatives.
- preservatives it is particularly advantageous to use lactic acid as a preservative.
- the present invention relates to a method for producing a cosmetic or dermatological composition as described above,
- the method comprises steps in which a suspension or a lyophilizate of the probiotically active bacterial strain or the probiotically active bacterial strains is first produced. If Lactobacillus strains are to be used in the composition in addition to the probiotically active bacterial strain or strains, two separate suspensions can first be prepared, which are then mixed with one another. The first suspension contains the at least one probiotically effective bacterial strain, and the second suspension contains at least one Lac tobacillus strain. Both suspensions can be prepared by inoculating cell material in water or a suitable buffer. The two suspensions can then be mixed with one another and combined with licochalcone A and the other components of the cosmetic or dermatological composition.
- composition of the present invention is produced with lyophilisates of the bacterial strains
- a lyophilisate can first be produced which comprises the at least one probiotic bacterial strain, and separately therefrom a second lyophilisate which comprises the at least one Lactobacillus strain.
- the two lyophilisates can then either be mixed with one another and then brought into contact with licochalcone A.
- first suspensions of the bacterial strains are mixed with one another, which are then subjected to freeze-drying, so that a lyophilisate is obtained which contains all of the bacterial strains.
- Me contains which are to be incorporated into the cosmetic or dermatological composition of the present invention.
- This lyophilizate which contains both at least one probiotically effective bacterial strain and at least one lactobacillus strain, is then mixed with licochalcone A and other cosmetic auxiliaries in order to provide the composition according to the invention.
- Freeze drying involves freezing a product, such as a bacterial suspension, under reduced pressure and adding heat so that the frozen water in the product can be removed by sublimation. Most products can be dried to 1-5% residual moisture.
- commercially available devices can be used for freeze-drying, such as the Lyovac TM devices from GEA (Berlin, Germany), the Gamma 2-20 freeze dryer LCM-1 from Christ (Osterode am Harz, Germany) or the Christ Martin TM Alpha 1-2 freeze dryer from Fisher Scientific GmbH (Schire, Germany).
- the invention relates to a method for the cosmetic or dermatological treatment of the skin, comprising steps in which the above-described cosmetic or dermatological composition of the present invention is applied to the skin of a subject, preferably a human.
- the area of skin to which the invention composition is applied has been carefully cleaned beforehand.
- cleaning can be done with a surfactant-containing cleaning agent.
- Cleaning agents which comprise benzoyl peroxide are particularly suitable for this purpose, although other substances can also be used in this context.
- the composition is an anhydrous composition.
- the bacterial strains can be present in the form of a lyophilizate in an oil phase. Only after the composition has been applied to the skin does the lyophilizate come into contact with water, which leads to the activation of the growth and metabolic activity of the bacteria.
- the oil phase can comprise oils customary in the field of cosmetics, such as, for example, lecithins, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil and castor oil.
- the composition is an aqueous composition. This means that the composition contains at least one aqueous phase in which the bacterial strains can be activated under suitable conditions.
- compositions of the present invention may be in the form of a cosmetic preparation which is used as a mask.
- the mask composition of the present invention is preferably based on an anhydrous powder which comprises at least one alginate, at least one calcium salt and at least one oil.
- the bacteria can be present as a lyophilizate in the oil phase, as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019007505.6A DE102019007505A1 (en) | 2019-10-28 | 2019-10-28 | Composition with probiotic bacteria and licochalcone A. |
PCT/EP2020/080215 WO2021083919A1 (en) | 2019-10-28 | 2020-10-28 | Composition containing prebiotic bacteria and licochalcone a |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4051222A1 true EP4051222A1 (en) | 2022-09-07 |
Family
ID=73043234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20800591.8A Pending EP4051222A1 (en) | 2019-10-28 | 2020-10-28 | Composition containing prebiotic bacteria and licochalcone a |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4051222A1 (en) |
DE (1) | DE102019007505A1 (en) |
WO (1) | WO2021083919A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10357452A1 (en) * | 2003-12-03 | 2005-06-30 | Beiersdorf Ag | Cosmetic preparations containing licochalcone A or an extract of Radix Glycyrrhizae inflatae, containing licochalcone A, and organic thickener |
GB201206599D0 (en) * | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
WO2016172196A1 (en) | 2015-04-20 | 2016-10-27 | Pätzold Bernhard | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
US20180289751A1 (en) * | 2015-05-05 | 2018-10-11 | The Regents Of The University Of California | Antimicrobial therapy |
US20180104283A1 (en) | 2016-10-13 | 2018-04-19 | Gregory Gary Caputy | Cosmetic skin treatment method |
WO2020001747A1 (en) * | 2018-06-26 | 2020-01-02 | Symrise Ag | Lactobacillus plantarum for skin care |
-
2019
- 2019-10-28 DE DE102019007505.6A patent/DE102019007505A1/en not_active Withdrawn
-
2020
- 2020-10-28 EP EP20800591.8A patent/EP4051222A1/en active Pending
- 2020-10-28 WO PCT/EP2020/080215 patent/WO2021083919A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021083919A1 (en) | 2021-05-06 |
DE102019007505A1 (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2705140B1 (en) | Novel lactic acid bacteria and compositions containing them | |
DE60023919T2 (en) | IMPROVED TOPICAL COMPOSITIONS WITH EXTRACELLULAR PRODUCTS OF PROBIOTIC BACTERIA AND USES THEREOF | |
DE3943838B4 (en) | Compositions for topical use containing cyclosporins | |
EP1963483A1 (en) | Novel lactobacillus strains and their use against helicobacter pylori | |
CN114901246A (en) | Novel skin care compositions | |
EP2255821A1 (en) | Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics | |
EP2424553A2 (en) | Cosmetic or dermatological composition containing hydrolyzates made of plant extracts | |
EP0357162B1 (en) | Process for modifying whey | |
EP4051230A1 (en) | Composition containing prebiotic bacteria and protector strains | |
WO2019029859A1 (en) | Composition for the care of the intimate- or vaginal area | |
CN114901252A (en) | Novel skin care compositions | |
CN114901245A (en) | Novel skin care compositions | |
CN114929193A (en) | Novel skin care compositions | |
EP4051222A1 (en) | Composition containing prebiotic bacteria and licochalcone a | |
DE60037343T2 (en) | BIFIDOBAKTERIA WITH THE ABILITY TO PREVENT DIARRHOE | |
WO2021018816A1 (en) | Alginate-based facial mask | |
EP0344786B1 (en) | Inhibiting agent for clostridia | |
KR102031354B1 (en) | Composition for improving microbial flora containing extract of cinnamomi ramulus | |
KR102031351B1 (en) | Composition for improving microbial flora containing extract of Trigonellae semen | |
DE102017113263A1 (en) | Pharmaceutical composition containing bacterial strains of the family Lactobacillaceae and whey | |
KR102031360B1 (en) | Composition for improving microbial flora containing extract of violae herba | |
DE2106154C3 (en) | Process for the production of a lactic acid bacteria preparation | |
EP4003270A1 (en) | Alginate-based facial mask | |
DE102019007508A1 (en) | Cosmetic composition | |
CN114901242A (en) | Novel skin care compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220331 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEIERSDORF AG Owner name: S-BIOMEDIC |